NO20006431L - Sammensetning for å forhindre og/eller behandle osteoporose og forandringer på grunn av menopausalsyndrom - Google Patents

Sammensetning for å forhindre og/eller behandle osteoporose og forandringer på grunn av menopausalsyndrom

Info

Publication number
NO20006431L
NO20006431L NO20006431A NO20006431A NO20006431L NO 20006431 L NO20006431 L NO 20006431L NO 20006431 A NO20006431 A NO 20006431A NO 20006431 A NO20006431 A NO 20006431A NO 20006431 L NO20006431 L NO 20006431L
Authority
NO
Norway
Prior art keywords
composition
prevent
menopausal syndrome
changes due
treat osteoporosis
Prior art date
Application number
NO20006431A
Other languages
English (en)
Other versions
NO20006431D0 (no
Inventor
Claudio Cavazza
Original Assignee
Sigma Tau Healthscience Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Healthscience Spa filed Critical Sigma Tau Healthscience Spa
Publication of NO20006431D0 publication Critical patent/NO20006431D0/no
Publication of NO20006431L publication Critical patent/NO20006431L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Det vises en sammensetning som kan ta form av et kosttilskudd eller av et reelt legemiddel som innbefatter som kjennetegner det aktive bestanddeler propionyl L-carnitin og isoflavon genistein for forebygging og/eller terapeutisk behandling av osteoporose og menopausesyndromet.
NO20006431A 1998-06-23 2000-12-15 Sammensetning for å forhindre og/eller behandle osteoporose og forandringer på grunn av menopausalsyndrom NO20006431L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT98RM000417A IT1299191B1 (it) 1998-06-23 1998-06-23 Composizione atta a prevenire e trattare l'osteoporosi e le alterazioni legate alla menopausa
PCT/IT1999/000174 WO1999066913A2 (en) 1998-06-23 1999-06-17 Composition for the prevention and/or treatment of osteoporosis and alterations due to menopause syndrome, comprising propionyl-l-carnitine and genistein

Publications (2)

Publication Number Publication Date
NO20006431D0 NO20006431D0 (no) 2000-12-15
NO20006431L true NO20006431L (no) 2001-02-22

Family

ID=11406005

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006431A NO20006431L (no) 1998-06-23 2000-12-15 Sammensetning for å forhindre og/eller behandle osteoporose og forandringer på grunn av menopausalsyndrom

Country Status (27)

Country Link
US (1) US6335038B1 (no)
EP (1) EP1089742B1 (no)
JP (1) JP4430233B2 (no)
KR (1) KR20010071541A (no)
CN (1) CN1306434A (no)
AR (1) AR018924A1 (no)
AT (1) ATE228367T1 (no)
AU (1) AU755272B2 (no)
BR (1) BR9911440A (no)
CA (1) CA2334875C (no)
DE (1) DE69904172T2 (no)
DK (1) DK1089742T3 (no)
EE (1) EE200000741A (no)
ES (1) ES2188177T3 (no)
HU (1) HU224957B1 (no)
IL (1) IL140163A0 (no)
IS (1) IS5764A (no)
IT (1) IT1299191B1 (no)
MA (1) MA26655A1 (no)
NO (1) NO20006431L (no)
NZ (1) NZ508877A (no)
PL (1) PL192118B1 (no)
PT (1) PT1089742E (no)
SK (1) SK19292000A3 (no)
TN (1) TNSN99132A1 (no)
TR (1) TR200003735T2 (no)
WO (1) WO1999066913A2 (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1302863B1 (it) * 1998-11-13 2000-10-10 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante e preventiva di alterazionitrombotiche e aterosclerotiche comprendente una carnitina ed un
US6476010B2 (en) 2000-03-10 2002-11-05 Hill's Pet Nutrition Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals
AU2001245977A1 (en) * 2000-03-23 2001-10-03 Interhealth Nutraceuticals Incorporated Method and composition for preventing or reducing the symptoms of menopause
US20020076470A1 (en) 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
US8669282B2 (en) 2000-10-31 2014-03-11 Hill's Pet Nutrition, Inc. Companion animal compositions including lipoic acid and methods of use thereof
IT1317079B1 (it) 2000-12-21 2003-05-26 Sigma Tau Ind Farmaceuti Uso della isovaleril l-carnitina per la preparazione di un medicamentoper la prevenzione e cura dell'osteoporosi.
JP2004519241A (ja) * 2001-03-09 2004-07-02 ソシエテ デ プロデユイ ネツスル ソシエテ アノニム 高齢化に伴う生理的障害を改善し寿命を延ばす組成物
BRPI0208103B8 (pt) * 2001-03-15 2021-05-25 Dsm Ip Assets Bv composição para a prevenção de osteoporose compreendendo uma combinação de isoflavonas e ácidos graxos poliinsaturados, seu uso, composição dietética, bem como formulação galênica que compreende a dita composição dietética
AUPR957001A0 (en) * 2001-12-19 2002-01-24 Novogen Research Pty Ltd Isoflavone conjugates, derivatives thereof and therapeutic methods involving same
EP1474129A1 (en) * 2002-02-15 2004-11-10 N.V. Nutricia Use of genistein in the manufacture of a medicament for the treatment of osteoporosis and obesity, and compositions containing genistein in combination with vitamin d and k
KR100542478B1 (ko) * 2002-08-28 2006-01-11 한경대학교 산학협력단 석류 유래 피토에스트로겐을 함유하는 건강기능식품
JP5102434B2 (ja) * 2002-09-09 2012-12-19 ネステク ソシエテ アノニム 皮膚品質を改良するための経口投与可能な組成物
KR100520408B1 (ko) * 2003-03-25 2005-10-10 주식회사 태평양 비만개선용 조성물
CN103211806B (zh) * 2003-05-27 2015-09-09 帝斯曼知识产权资产管理有限公司 新颖的营养药物性组合物及其用途
JP2005187454A (ja) * 2003-12-05 2005-07-14 Sankyo Co Ltd ビタミンｅ含有ｌｄｌ低下剤及び／又は動脈硬化抑制剤組成物
US20080305094A1 (en) * 2004-01-28 2008-12-11 Nestec S.A. Nutritional Composition for Improving Skin Condition and Preventing Skin Diseases
KR100739280B1 (ko) * 2004-02-03 2007-07-12 가부시끼가이샤 고또스기 운남 홍두삼 유래 이소탁시레시놀을 성분으로 하는골다공증 치료ㆍ예방약
EP2208422B1 (en) * 2004-03-17 2015-11-25 Nestec S.A. Compositions and methods for reducing or preventing obesity
CN100351248C (zh) * 2004-07-05 2007-11-28 南京大学 染料木素衍生物及其制法和用途
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
DE102004060314A1 (de) * 2004-12-08 2006-08-31 Beiersdorf Ag Wirkstoffkombinationen aus einem oder mehreren Isoflavonoiden und Carnitin und/oder einem oder mehreren Acyl-Carnitinen
CA2592389C (en) 2004-12-29 2013-05-14 Hill's Pet Nutrition, Inc. Methods for inhibiting a decline in learning and/or memory in animals
EP1841421A4 (en) * 2005-01-10 2008-01-02 Hormos Medical Ltd USE OF LIGNAN FOR PREPARING A COMPOSITION FOR PREVENTING OR AIDING SYMPTOMS RELATED TO ESTROGEN DEFICIENCY
DE102005011779A1 (de) * 2005-03-11 2006-09-14 Bayer Healthcare Ag Endoparasitizide Mittel
AU2006268787B2 (en) * 2005-07-08 2012-02-02 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of a combination comprising L-carnitine or alkanoyl L-carnitine, lipid solubl benzoquinone and omega-3-polyunsaturated fatty acid for the preparation of a dietary supplement or medicament for the treatment of corneal diseases
AU2006267068B2 (en) 2005-07-14 2011-01-06 Hill's Pet Nutrition, Inc. Method for prolonging the life of animals
CN1939534B (zh) * 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
KR20080068850A (ko) * 2005-10-14 2008-07-24 디에스엠 아이피 어셋츠 비.브이. 레스베라트롤을 포함하는 기능성식품 조성물의 신규한 용도
JP2009514824A (ja) 2005-11-02 2009-04-09 ネステク ソシエテ アノニム 雄の哺乳動物における体脂肪の蓄積を低減するためのイソフラボン組成物及びその使用方法
CN101389328B (zh) 2006-02-28 2013-04-24 雀巢技术公司 诱导骨生长和抑制骨流失的组合物和方法
CA2643973A1 (en) 2006-02-28 2007-09-07 Council Of Scientific And Industrial Research Pharmaceutical composition containing butea isoflavones for the prevention /treatment of bone disorders and a process for the preparation thereof
WO2007116052A1 (en) * 2006-04-12 2007-10-18 Unilever Plc Oral composition comprising dha and genistein for enhancing skin properties
EP2004169B1 (en) * 2006-04-12 2012-08-08 Unilever PLC Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin
PL2189155T3 (pl) * 2006-04-12 2016-07-29 Unilever Nv Doustna kompozycja o przeciwstarzeniowym działaniu na skórę
US20080108696A1 (en) 2006-08-02 2008-05-08 Brinton Roberta D Phytoestrogenic Formulations for Alleviation or Prevention of Neurodegenerative Diseases
US8680140B2 (en) * 2006-08-02 2014-03-25 University Of Southern California Phytoestrogenic formulations for alleviation or prevention of menopausal symptoms
US20080200441A1 (en) * 2007-02-14 2008-08-21 University Of Southern California Estrogen receptor modulators associated pharmaceutical compositions and methods of use
PT2343292E (pt) 2008-09-10 2014-11-04 Kaken Pharma Co Ltd Novo derivado de prostaglandina i2
US20110091435A1 (en) * 2008-10-24 2011-04-21 University Of Southern California Phytoestrogenic formulations for alleviation or prevention of hair loss
JP2012508267A (ja) * 2008-11-11 2012-04-05 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ セルライトの処置に有用な化合物
KR101158856B1 (ko) 2009-05-12 2012-06-25 한국생명공학연구원 콩잎 추출물 또는 이의 분획물을 유효성분으로 함유하는 비만, 고지혈증, 동맥경화, 지방간, 당뇨 또는 대사증후군의 예방 또는 치료용 조성물
CN102917703B (zh) * 2010-03-08 2015-08-19 科研制药株式会社 新型ep4激动剂
JP2013530170A (ja) * 2010-06-16 2013-07-25 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ 神経組織における神経発生を増大させるための方法における使用のためのアセチル−カルニチン
WO2012011572A1 (ja) * 2010-07-23 2012-01-26 国立大学法人大阪大学 拡張不全型心不全治療薬
IT201700116392A1 (it) * 2018-04-03 2019-10-03 Composizione per somministrazione orale aventi benefico effetto sulla salute della donna in menopausa

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1275434B (it) * 1995-05-19 1997-08-07 Farmila Farma Milano Composizioni farmaceutiche e/o dietetiche ad attivita' antiossidante
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
US5702752A (en) * 1996-03-13 1997-12-30 Archer Daniels Midland Company Production of isoflavone enriched fractions from soy protein extracts
US6139872A (en) * 1996-08-14 2000-10-31 Henkel Corporation Method of producing a vitamin product
EP1021177A4 (en) * 1997-02-04 2002-05-15 John V Kosbab COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF VASCULAR DEGENERATIVE DISEASES

Also Published As

Publication number Publication date
JP4430233B2 (ja) 2010-03-10
CA2334875A1 (en) 1999-12-29
CA2334875C (en) 2009-05-12
EE200000741A (et) 2002-04-15
IT1299191B1 (it) 2000-02-29
KR20010071541A (ko) 2001-07-28
EP1089742A2 (en) 2001-04-11
IL140163A0 (en) 2002-02-10
ES2188177T3 (es) 2003-06-16
US6335038B1 (en) 2002-01-01
PT1089742E (pt) 2003-04-30
BR9911440A (pt) 2001-03-20
HU224957B1 (en) 2006-04-28
DE69904172T2 (de) 2003-08-28
PL192118B1 (pl) 2006-09-29
DE69904172D1 (de) 2003-01-09
MA26655A1 (fr) 2004-12-20
HUP0102879A3 (en) 2002-12-28
AR018924A1 (es) 2001-12-12
EP1089742B1 (en) 2002-11-27
TNSN99132A1 (fr) 2005-11-10
CN1306434A (zh) 2001-08-01
ITRM980417A1 (it) 1999-12-23
ITRM980417A0 (it) 1998-06-23
HUP0102879A2 (hu) 2002-03-28
AU4390999A (en) 2000-01-10
DK1089742T3 (da) 2003-03-24
NZ508877A (en) 2002-09-27
AU755272B2 (en) 2002-12-05
PL345030A1 (en) 2001-11-19
IS5764A (is) 2000-12-08
WO1999066913A2 (en) 1999-12-29
WO1999066913A3 (en) 2000-04-20
ATE228367T1 (de) 2002-12-15
TR200003735T2 (tr) 2001-03-21
NO20006431D0 (no) 2000-12-15
JP2002518437A (ja) 2002-06-25
SK19292000A3 (sk) 2001-08-06

Similar Documents

Publication Publication Date Title
NO20006431L (no) Sammensetning for å forhindre og/eller behandle osteoporose og forandringer på grunn av menopausalsyndrom
CA2341973A1 (en) Antioxidant composition comprising acetyl l-carnitine and .alpha.-lipoic acid
DK1064009T3 (da) Anvendelse af ekstrakter af irisplanter og Cimicifuga racemosa og tectorigenin som estrogenagtigt organselektivt lægemiddel uden uterotrop virkning
NO20006430L (no) Neurobeskyttende sammensetning for forhindring og/eller behandling av nerve- og atferdsforandringer på grunn av angsttilstander eller depresjoner
BR0109912A (pt) Novas combinações antelmìnticas
TR200002770T2 (tr) Estrojene bağlı bozuklukların tedavisi
NO20021640L (no) Sammensetning til forebygging og/eller behandling av kretslöpsykdommer som omfatter derivater av L-karnitin ogekstrakter av Gingo biloba
TR200003737T1 (tr) Diyet takviyesi ya da ilaç olarak kullanılan bileşim
NO20013787D0 (no) Soyaekstrakt som inneholder lipider, fremgangsmåte for dets fremstilling og farmasöytiske og kosmetiske blandinger
WO2000007581A3 (en) Antioxidant, antiproliferous composition, comprising a carnitine and a carotenoid
AU5634500A (en) Dietary calcium as a supplement to vitamin d compound treatment of multiple sclerosis
WO2000000183A3 (en) Antioxidant, cytostatic and sustained energy composition which ameliorates the metabolic utilization of glucose comprising acetyl-l-carnitine and a catechin
CA2350220A1 (en) Antioxidant composition comprising propionyl l-carnitine and a flavonoid against thrombosis and atherosclerosis
ATE239504T1 (de) Zusammensetzung zur vorbeugung und/oder behandlung von störungen aufgrund von abnormalen fettstoffmetabolismus, enthaltend l-carnitin und chitosan
NO952601L (no) Oligonukleotider for inhibering av ekspresjon av isoprenylprotein-transferaser
ATE339962T1 (de) Zubereitungen zur behandlung von lupus
BR0309055A (pt) Uso combinado de l-carnitina, acetil l-carnitina e propionil l-carnitina para o tratamento da oligoastenoteratospermia
TR200200015T2 (tr) L-Karnitin ve türevleri ile crataegus ekstreleri içeren kardiyoaktif bileşim
EP1319405A1 (en) Composition comprising a mixture of bioflavonols
SE0200256D0 (sv) New composition, methods and use
KR940003550A (ko) 노인성 치매 예방 및 치료방법
MX9709684A (es) Uso de derivados de vitamina d4 para tratamiento de trastornos de la piel.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application